A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer

Heeman Kim, Kyong Joo Lee, Jihye Cha, Moon Jae Chung, Seungmin Bang, Jinsil Seong, Si Young Song, Seung Woo Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. Methods: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m2, twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. Results: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75 %) had extrahepatic cholangiocarcinoma, two patients (10 %) had intrahepatic cholangiocarcinoma, and three patients (15 %) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15 %), and stable disease was achieved in 14 patients (70 %). The overall response rate was 15 %, and the disease stabilization rate was 85 %. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15 %), neutropenia (10 %), and nausea (10 %). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. Conclusions: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.

Original languageEnglish
Pages (from-to)861-865
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume74
Issue number4
DOIs
Publication statusPublished - 2014 Aug 17

Fingerprint

Chemoradiotherapy
Biliary Tract Neoplasms
Toxicity
Chemotherapy
Radiotherapy
Tomography
Tumors
Stabilization
Cholangiocarcinoma
Gallbladder Neoplasms
Neutropenia
Thrombocytopenia
Nausea
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Kim, Heeman ; Lee, Kyong Joo ; Cha, Jihye ; Chung, Moon Jae ; Bang, Seungmin ; Seong, Jinsil ; Song, Si Young ; Park, Seung Woo. / A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer. In: Cancer Chemotherapy and Pharmacology. 2014 ; Vol. 74, No. 4. pp. 861-865.
@article{828f5674795646dab8aaced907e409e2,
title = "A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer",
abstract = "Purpose: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. Methods: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m2, twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. Results: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75 {\%}) had extrahepatic cholangiocarcinoma, two patients (10 {\%}) had intrahepatic cholangiocarcinoma, and three patients (15 {\%}) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15 {\%}), and stable disease was achieved in 14 patients (70 {\%}). The overall response rate was 15 {\%}, and the disease stabilization rate was 85 {\%}. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15 {\%}), neutropenia (10 {\%}), and nausea (10 {\%}). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. Conclusions: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.",
author = "Heeman Kim and Lee, {Kyong Joo} and Jihye Cha and Chung, {Moon Jae} and Seungmin Bang and Jinsil Seong and Song, {Si Young} and Park, {Seung Woo}",
year = "2014",
month = "8",
day = "17",
doi = "10.1007/s00280-014-2565-y",
language = "English",
volume = "74",
pages = "861--865",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer. / Kim, Heeman; Lee, Kyong Joo; Cha, Jihye; Chung, Moon Jae; Bang, Seungmin; Seong, Jinsil; Song, Si Young; Park, Seung Woo.

In: Cancer Chemotherapy and Pharmacology, Vol. 74, No. 4, 17.08.2014, p. 861-865.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer

AU - Kim, Heeman

AU - Lee, Kyong Joo

AU - Cha, Jihye

AU - Chung, Moon Jae

AU - Bang, Seungmin

AU - Seong, Jinsil

AU - Song, Si Young

AU - Park, Seung Woo

PY - 2014/8/17

Y1 - 2014/8/17

N2 - Purpose: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. Methods: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m2, twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. Results: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75 %) had extrahepatic cholangiocarcinoma, two patients (10 %) had intrahepatic cholangiocarcinoma, and three patients (15 %) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15 %), and stable disease was achieved in 14 patients (70 %). The overall response rate was 15 %, and the disease stabilization rate was 85 %. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15 %), neutropenia (10 %), and nausea (10 %). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. Conclusions: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.

AB - Purpose: S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer. Methods: Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m2, twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required. Results: Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75 %) had extrahepatic cholangiocarcinoma, two patients (10 %) had intrahepatic cholangiocarcinoma, and three patients (15 %) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15 %), and stable disease was achieved in 14 patients (70 %). The overall response rate was 15 %, and the disease stabilization rate was 85 %. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15 %), neutropenia (10 %), and nausea (10 %). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively. Conclusions: This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.

UR - http://www.scopus.com/inward/record.url?scp=84925547522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925547522&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2565-y

DO - 10.1007/s00280-014-2565-y

M3 - Article

C2 - 25129491

AN - SCOPUS:84925547522

VL - 74

SP - 861

EP - 865

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -